1. Home
  2. QUAD vs DRUG Comparison

QUAD vs DRUG Comparison

Compare QUAD & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QUAD
  • DRUG
  • Stock Information
  • Founded
  • QUAD 1971
  • DRUG 2019
  • Country
  • QUAD United States
  • DRUG United States
  • Employees
  • QUAD N/A
  • DRUG N/A
  • Industry
  • QUAD Publishing
  • DRUG Pharmaceuticals and Biotechnology
  • Sector
  • QUAD Consumer Discretionary
  • DRUG Health Care
  • Exchange
  • QUAD Nasdaq
  • DRUG Nasdaq
  • Market Cap
  • QUAD 261.9M
  • DRUG 233.2M
  • IPO Year
  • QUAD 2010
  • DRUG N/A
  • Fundamental
  • Price
  • QUAD $6.03
  • DRUG $32.62
  • Analyst Decision
  • QUAD Strong Buy
  • DRUG Strong Buy
  • Analyst Count
  • QUAD 2
  • DRUG 5
  • Target Price
  • QUAD $9.45
  • DRUG $83.25
  • AVG Volume (30 Days)
  • QUAD 366.6K
  • DRUG 26.6K
  • Earning Date
  • QUAD 04-29-2025
  • DRUG 05-20-2025
  • Dividend Yield
  • QUAD 5.08%
  • DRUG N/A
  • EPS Growth
  • QUAD N/A
  • DRUG N/A
  • EPS
  • QUAD N/A
  • DRUG N/A
  • Revenue
  • QUAD $2,646,800,000.00
  • DRUG N/A
  • Revenue This Year
  • QUAD N/A
  • DRUG N/A
  • Revenue Next Year
  • QUAD N/A
  • DRUG N/A
  • P/E Ratio
  • QUAD N/A
  • DRUG N/A
  • Revenue Growth
  • QUAD N/A
  • DRUG N/A
  • 52 Week Low
  • QUAD $4.06
  • DRUG $0.93
  • 52 Week High
  • QUAD $9.13
  • DRUG $79.02
  • Technical
  • Relative Strength Index (RSI)
  • QUAD 65.47
  • DRUG 51.74
  • Support Level
  • QUAD $4.50
  • DRUG $29.59
  • Resistance Level
  • QUAD $5.51
  • DRUG $32.75
  • Average True Range (ATR)
  • QUAD 0.32
  • DRUG 2.23
  • MACD
  • QUAD 0.13
  • DRUG 0.21
  • Stochastic Oscillator
  • QUAD 94.43
  • DRUG 54.14

About QUAD Quad Graphics Inc

Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America and others countries. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market..

About DRUG Bright Minds Biosciences Inc.

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Share on Social Networks: